CLINICAL TRIALS PROFILE FOR ERAXIS

All Clinical Trials for ERAXIS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00496197 ↗	Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis	Completed	Pfizer	Phase 4	2007-07-01	The purpose of this study is to further evaluate the safety and effectiveness of intravenous anidulafungin (Eraxis™) in patients with a diagnosis of candidemia or invasive candidiasis, which is a fungus infection of the blood or tissue. Currently the drug is approved for treatment using a daily dose of IV medication until 14 days after the fungus disappears from the blood. This study will evaluate the effectiveness of intravenous anidulafungin when it is administered for 5-28 days followed by oral antifungal medication. Study patients will be assessed for response to treatment throughout the study drug treatment period.
NCT00531479 ↗	Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis	Completed	Pfizer	Phase 3	2008-07-01	This study compares the effectiveness and safety of the combination of anidulafungin and voriconazole compared to that of voriconazole alone (which is generally considered the standard of care) for the treatment of Invasive Aspergillosis.
NCT00548262 ↗	This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis	Completed	Pfizer	Phase 4	2008-02-01	The primary objective is to estimate global response rate. Clinical, microbiological and global response rates and its 95% confidence intervals will be computed. No hypotheses will be tested.
NCT00620074 ↗	Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)	Terminated	Pfizer	Phase 4	2008-08-01	This study will test the effectiveness and the safety of giving two antifungal agents (voriconazole and anidulafungin) together to treat invasive aspergillosis in patients who are unable to tolerate polyene therapy.
NCT00672841 ↗	β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients	Completed	Pfizer	N/A	2008-06-01	This is a single center, prospective, open label assessment of β-D-glucan surveillance with preemptive anidulafungin therapy versus standard care for the prevention of invasive candidiasis in at-risk surgical intensive care unit (SICU) patients. Subjects will be stratified by APACHE II score and randomized in 3:1 fashion to either biweekly surveillance using the β-D-glucan assay or standard care. Subjects in the active monitoring arm will receive intravenous anidulafungin should the β-D-glucan exceed 60 pg/mL on a single determination. Subjects in the standard care arm will have biweekly blood draws for β-D-glucan, but the specimens will be batched and tested retrospectively. Antifungal use in the standard care arm is at the discretion of the treating physicians. The primary study end-points are the feasibility of a preemptive antifungal strategy in a SICU setting, β-D-glucan test characteristics, and the safety and tolerability of preemptive anidulafungin. Risks associated with study participation include the risks associated with blood draws, study drug related side effects, and the potential for loss of confidentiality.
NCT00672841 ↗	β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients	Completed	Duke University	N/A	2008-06-01	This is a single center, prospective, open label assessment of β-D-glucan surveillance with preemptive anidulafungin therapy versus standard care for the prevention of invasive candidiasis in at-risk surgical intensive care unit (SICU) patients. Subjects will be stratified by APACHE II score and randomized in 3:1 fashion to either biweekly surveillance using the β-D-glucan assay or standard care. Subjects in the active monitoring arm will receive intravenous anidulafungin should the β-D-glucan exceed 60 pg/mL on a single determination. Subjects in the standard care arm will have biweekly blood draws for β-D-glucan, but the specimens will be batched and tested retrospectively. Antifungal use in the standard care arm is at the discretion of the treating physicians. The primary study end-points are the feasibility of a preemptive antifungal strategy in a SICU setting, β-D-glucan test characteristics, and the safety and tolerability of preemptive anidulafungin. Risks associated with study participation include the risks associated with blood draws, study drug related side effects, and the potential for loss of confidentiality.
NCT00734500 ↗	Anidulafungin PK in Infants and Toddlers	Completed	Michael Cohen-Wolkowiez	Phase 1	2008-01-01	This is a prospective, open-label, single center, pharmacokinetic study of anidulafungin in infants and toddlers less than 24 months of age with suspected serious infection. There will be up to 24 subjects enrolled; each will receive anidulafungin. Patients will receive anidulafungin 3 mg/kg loading dose on day 1 of study and will receive 1.5 mg/kg every 24 hours on study days 2-5.Plasma pharmacokinetics will be evaluated using a limited sampling scheme. We hypothesize that the PK parameters of anidulafungin will not differ from those observed in older children and adults.

Clinical Trial Conditions for ERAXIS

Condition Name

Condition Name for ERAXIS
Intervention	Trials
Candidiasis	3
Fungemia	3
Mycoses	2
Aspergillosis	2

Condition MeSH

Condition MeSH for ERAXIS
Intervention	Trials
Candidiasis	6
Candidiasis, Invasive	4
Infections	3
Infection	3

Clinical Trial Locations for ERAXIS

Trials by Country

Trials by Country for ERAXIS
Location	Trials
United States	55
Brazil	12
Canada	6
Russian Federation	5
Italy	5

Trials by US State

Trials by US State for ERAXIS
Location	Trials
Michigan	5
Texas	5
North Carolina	5
Florida	4
California	4

Clinical Trial Progress for ERAXIS

Clinical Trial Phase

Clinical Trial Phase for ERAXIS
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	4
Phase 1	1

Clinical Trial Status

Clinical Trial Status for ERAXIS
Clinical Trial Phase	Trials
Completed	8
Terminated	3

Clinical Trial Sponsors for ERAXIS

Sponsor Name

Sponsor Name for ERAXIS
Sponsor	Trials
Pfizer	8
Duke University	1
Michael Cohen-Wolkowiez	1

Sponsor Type

Sponsor Type for ERAXIS
Sponsor	Trials
Industry	8
Other	5
NIH	1

ERAXIS Market Analysis and Financial Projection

Last updated: May 1, 2026

Eraxis (anidulafungin): What’s in Clinical Trials, and Where Does the Market Go?

Is there an active clinical-trials pipeline for Eraxis (anidulafungin)?

Based on the publicly available, consolidated trial landscape, the current clinical activity for Eraxis (anidulafungin) is not driven by new, registrational Phase 3 programs. The historically largest and pivotal evidence base remains earlier antifungal-infection development work, and the post-approval period largely centers on:

• Expanded labeling and clinical-use evidence (practice-based studies, comparative analyses using existing dosing frameworks).
• Population and safety characterization in real-world or observational settings.
• Formulation/dosing optimization is limited in public registrational scope versus the initial Phase 3 dossier.

What this means for “clinical trials update”: the incremental value in 2024-2026 is primarily evidence consolidation and utilization studies rather than a pipeline that materially changes future market access. Public trial trackers continue to list studies involving anidulafungin in specific clinical contexts, but the market-shaping readout (new Phase 3 outcomes that expand indications or shift standard of care) is not evident in the public record.

How does Eraxis perform in the current antifungal market?

Eraxis competes inside the invasive candidiasis and candidemia segment and broader invasive fungal infections use-cases where echinocandins are standard-of-care. The competitive set includes:

• Mycamine (micafungin)
• Cancidas (caspofungin)
• Generic echinocandins where available by market and regulatory status
• Alternative antifungal classes (azoles and polyenes) for specific phenotypes and lines of therapy

Commercial dynamics that matter:

1. Class stability: Echinocandins remain first-line in many invasive candidiasis pathways, especially in ICU and high-acuity settings.
2. Formulary behavior: Hospitals tend to favor 1-2 echinocandins for stewardship and procurement leverage, producing “stickiness” that can maintain demand even as competitors expand.
3. Dosing convenience and tolerability: Standard anidulafungin dosing (loading then maintenance for the approved regimens) is entrenched in hospital protocols.
4. Biosafety stewardship: Antifungal stewardship programs increasingly drive narrower selection, but echinocandin positioning stays strong for candidemia.

What does market access look like (pricing pressure vs demand resilience)?

Eraxis faces typical post-patent/late-life brand pricing pressure in many geographies, but echinocandin demand is less elastic than many oncology categories due to:

• high acuity indications,
• standardized guideline use,
• hospital formulary controls that limit substitution within the same class.

The net effect in mature markets: demand remains resilient, but unit pricing and share can be compressed when generics or lower-cost options exist.

---

Market Projection: What baseline growth rate is plausible for Eraxis?

How should Eraxis market growth be modeled?

For a mature, late-life antifungal like anidulafungin, market modeling typically decomposes into:

• Incidence and hospital utilization for invasive candidiasis,
• Penetration of echinocandins vs azoles/polene strategies,
• Share within echinocandins (formulary and contracting),
• Price erosion (generic erosion, contracting, and tender cycles).

A “clinical trials update” that does not include new Phase 3 expansion means the projection rests mostly on epidemiology and class-level demand rather than label expansion.

Directionally, projection for Eraxis is stable-to-slow growth in mature markets with downside risk from:

• broader generic penetration in tender-based procurement,
• class switching in specific hospital networks,
• aggressive contracting favoring the lowest-cost echinocandin.

Upside drivers are limited but include:

• increases in invasive fungal infection recognition and coding,
• ongoing guideline adherence to echinocandins in high-risk candidemia,
• stewardship-led consolidation that preserves formulary share.

---

Competitor and substitution map

Which drugs compete directly with Eraxis, and how do they change the outlook?

Eraxis competes in the same antifungal class and disease settings as:

• Micafungin (Mycamine): often benefits from existing formulary lock-in in many hospital networks.
• Caspofungin (Cancidas): competes where hospital procurement favors it.
• Generic echinocandins: exert the largest commercial pressure on brand pricing.

Implication for business planning: without a registrational Phase 3 expansion, Eraxis value depends on maintaining contracting leverage and stewardship-prescriber familiarity, not on a pipeline re-rate.

---

Clinical and regulatory context (why the pipeline looks “quiet”)

What does the approval and evidence base already cover?

Eraxis is an echinocandin approved for invasive candidiasis indications and is used broadly in guideline-based management of invasive fungal infections caused by susceptible Candida species. Publicly available product information and labeling history provide the dosing and efficacy framework that current practice-based studies build on.

Clinical trial activity in the public domain remains more focused on:

• safety surveillance,
• observational outcomes,
• comparative effectiveness using the already-established dosing regimens.

In this setting, the “update” is not a new indication story; it is an evidence-maintenance story.

---

Investment and R&D relevance

Does Eraxis have a credible path to a market re-acceleration via R&D?

Given the maturity of anidulafungin and the absence of widely publicized new registrational Phase 3 outcomes that expand indication breadth, R&D value capture for Eraxis typically concentrates on:

• life-cycle management (non-registrational studies),
• formulation or supply optimization where relevant,
• new evidence for stewardship protocols.

If the objective is a market re-acceleration, the public record does not point to near-term label expansion as the mechanism.

---

Key Takeaways

• Eraxis clinical-trials momentum is not being driven by new registrational Phase 3 expansion in the public trial landscape; current activity is mostly evidence consolidation.
• Market demand remains supported by echinocandin guideline use for invasive candidiasis, with growth tied more to incidence/utilization than to new labeling.
• Commercial upside is limited without new indications; brand economics face price pressure where generics and contracting reduce unit revenue.
• Projection for Eraxis is best treated as stable-to-slow growth in mature markets with pricing and share as the primary swing factors.

---

FAQs

1. Is Eraxis currently launching new Phase 3 trials for new indications?
   No major registrational Phase 3 indication-expansion program is evident in the public trial landscape.

2. What drives Eraxis demand most: new clinical data or guideline utilization?
   Guideline utilization and invasive candidiasis incidence drive demand more than new label-changing trials.

3. Which drugs most threaten Eraxis pricing?
   Competing echinocandins and generic echinocandin options via tender and formulary contracting.

4. What is the main risk to Eraxis unit economics?
   Price erosion and share compression in hospital procurement where lower-cost options win contracts.

5. What is the main upside scenario?
   Increased echinocandin utilization through stewardship protocols that preserves or expands Eraxis formulary placement.

---

References

[1] FDA. ERAxis (anidulafungin) prescribing information. U.S. Food and Drug Administration.
[2] EMA. Eraxis (anidulafungin) product information. European Medicines Agency.
[3] ClinicalTrials.gov. Anidulafungin (Eraxis) clinical trials database. National Library of Medicine.
[4] IDSA. Clinical practice guidelines for the management of candidiasis. Infectious Diseases Society of America.